Wait for confirmation (daily close above 10 EMA at 91.08 with positive MACD cross and RSI above 50) or initiate at low-end sizing (0.5% portfolio) as a probe trade with put protection near 87 strike; do not average down on failure.

• RSI at 26.5 lacks confirmed bullish divergence; no single oversold reading is a buy signal per technical report
• ATR is rising with expanding volatility bands; this is a trend continuation pattern, not mean-reversion
• Price sits 58 cents above 200 SMA at 86.52; most recent daily range was $1.60, leaving minimal margin for error
• Entry at 87.10 with stop at 84.90 ($2.20 risk) is only 38 cents below technical invalidation at 86.52
• Forward PE of 10.21x assumes forward EPS of $8.53 versus trailing EPS of $3.79 (125% recovery assumption)
• PEG of 0.21 signals aggressive earnings recovery assumptions, not necessarily value
• OCF ramp from $0.80 billion to $6.35 billion is partially mechanical due to $5.24 billion impairment in Q3 2025
• Stop at 1x ATR is too tight in rising volatility environment
• Macro support is not bulletproof: 76 billion in debt faces refinancing headwinds under higher-for-longer rates
• PBM regulatory overhang remains multi-quarter risk, not single-event risk
• Aggressive analyst over-rides trader's own caution (scaling-in recommendation) with conviction trader did not express
• 8:1 reward-to-risk ratio is meaningless without probability weighting; technical structure suggests low win probability

→ vs aggressive: RSI coiled spring narrative contradicts technical report which states no confirmed bullish divergence and RSI can stay below 30 in extended downtrends

→ vs aggressive: Volatility geometry is inverted: lower band touch in EXPANDING bands (rising ATR) signals trend continuation, not mean-reversion bounce

→ vs aggressive: 200 SMA at 86.52 is unconfirmed support; thesis explicitly states break below 86.52 invalidates setup, yet price hasn't confirmed level holds

→ vs aggressive: Forward PE of 10.21x embeds 125% earnings recovery assumption that ignores documented impairment history ($5.24 billion in Q3 2025)

→ vs aggressive: OCF 'eightfold improvement' omits $5.24 billion impairment distortion; not like-for-like comparison

→ vs aggressive: Stop at 84.90 gives only 38 cents buffer below 86.52 invalidation level; practically fragile in rising ATR environment

→ vs aggressive: 8:1 reward-to-risk is meaningless without probability; technical structure (all MAs overhead, MACD lengthening, no divergence, VWMA rolling over) suggests win probability well below 12.5%

→ vs aggressive: PBM regulatory risk is multi-quarter process, not single discrete event; 5% drop framing underestimates binary nature of regulatory outcomes

→ vs aggressive: Higher-for-longer is headwind for 76 billion in debt refinancing, not just support for yield

→ vs aggressive: Traders own analysis recommended scaling in, not full conviction; aggressive analyst over-rides this caution

BUY at $87.10, but with a modified construction: 0.75% initial position with stop at $84.90, add second 0.75% tranche on daily close above $91.08 with RSI above 40, move stop to breakeven after second tranche fills. Do not average down if price breaks $86.52.

• Valuation case is real: $111 billion market cap, 0.58 beta, 3% covered dividend, accelerating FCF, forward PE of 10.21
• Street target of $116 versus $87.10 entry is legitimate, Omnicare resolution clears multi-year legal overhang
• Macro backdrop supportive: 96% odds of no cuts, 8% recession odds favor defensive yield names
• Aggressive analyst's RSI bounce claim is unverifiable narrative; OCF ramp framing as 'eightfold improvement' misleading due to Q3 2025 $5.24B impairment distortion
• Conservative analyst's confirmation entry at $91.08 worsens risk/reward math materially
• Forward PE of $8.53 assumes 125% recovery from $3.79 trailing EPS, but anchored to visible cash flow trajectory: $1.77B quarterly debt paydown, $8B TTM FCF, management guidance raised
• PBM reform is slow-grind asymmetric downside risk, but multiple already compressed so partial resolution is re-rating catalyst
• Correctly identified probability at 50-60% with 5-8 to 1 reward on successes, 1 to 1 loss on failures
• Trade construction: 0.75% initial + 0.75% on confirmation respects both fundamental merit and technical uncertainty

→ vs aggressive: RSI bounce claim is unverifiable narrative; OCF 'eightfold improvement' ignores Q3 2025 impairment distortion; calling it 'high conviction' overrides trader's own 'scaling in' caution

→ vs conservative: Waiting for full confirmation (close above $91.08 with MACD cross and RSI above 50) materially worsens entry and R/R math; over-engineering with 0.5% sizing and put hedge treats a 2% risk position like a 10% position